Thymosin Alpha-1

Thymosin alpha-1 is a 28-amino-acid peptide that occurs naturally within the immune system. In the research literature it is studied as an immune-modulating peptide, examined in models of T-cell function and immune signaling. VANTA supplies it strictly as a reference-grade compound for laboratory research, not for any human or veterinary use.

In preclinical and in-vitro literature, thymosin alpha-1 is examined in the context of T-cell function, immune modulation, and related signaling pathways. These are observations described in research models only and do not establish any outcome in humans. VANTA provides the peptide so qualified investigators can reference the primary literature directly.

The thymosin alpha-1 peptide ships as a lyophilized powder. Each lot is assessed by reversed-phase HPLC for chromatographic purity, and identity is confirmed by mass spectrometry. This lets researchers attribute results to the intended peptide rather than to related impurities.

Store the sealed lyophilized vial at -20C. Researchers generally reconstitute with an appropriate solvent immediately before experimental use, following their own institutional protocols, then keep the solution refrigerated and protected from repeated freeze-thaw cycles. These are general laboratory handling notes, not instructions for any in-vivo application.

Yes. Every batch of thymosin alpha-1 ships with a per-batch Certificate of Analysis documenting the HPLC purity result and the mass-spec identity confirmation for that specific lot. This per-lot documentation lets a laboratory tie each experiment to a traceable batch and its underlying analytical data.

No. Thymosin alpha-1 from VANTA is intended strictly for laboratory and in-vitro research use by qualified professionals. It is not a drug, supplement, or food, and is not intended for human consumption, administration, or any clinical, diagnostic, or therapeutic use. Researchers are responsible for complying with all applicable regulations.